Development of 2A peptide-based strategies in the design of multicistronic vectors
Top Cited Papers
- 1 May 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 5 (5), 627-638
- https://doi.org/10.1517/14712598.5.5.627
Abstract
As science progresses in its understanding of diseases and their treatment, advances have been made in the biotechnology used in disease therapy. Most gene therapy approaches utilise viral vectors to deliver genes of interest. However, multiple proteins are often involved in disease processes and there is often a need to efficiently deliver more than one gene. Researchers have employed several strategies to accomplish this goal. When designing vectors to express multiple genes, there are several factors that need to be taken into account, including cell type, the activity of the protein of interest and s-ubcellular protein localisation. In most cases, it is ideal for each protein to be expressed at comparable levels, a leading issue with traditional strategies for multigene expression. This review describes some of the techniques that have been used to express multiple genes, and will focus on the use of 2A peptides or 2A peptide-like sequences in the design of multicistronic v-ectors that may alleviate s...Keywords
This publication has 95 references indexed in Scilit:
- Addendum: Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004
- Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neuronsGene Therapy, 2001
- Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategyGene Therapy, 2001
- Viral Vectors for Gene TransferDrugs, 2000
- Reconstitution of a metabolic pathway with triple-cistronic IRES-containing retroviral vectors for correction of tetrahydrobiopterin deficiencyThe Journal of Gene Medicine, 2000
- Production of Interleukin-12 as a Self-Processing 2A PolypeptideJournal of Interferon & Cytokine Research, 1999
- Characterization of an Internal Ribosomal Entry Segment Within the 5′ Leader of Avian Reticuloendotheliosis Virus Type A RNA and Development of Novel MLV-REV-Based Retroviral VectorsHuman Gene Therapy, 1997
- Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoterGene, 1996
- Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12Human Gene Therapy, 1994
- Dicistronic transcription units for gene expression in mammalian cellsGene, 1993